Submitted by Anonymous (not verified) on 23 October 2023 - 15:33
Human medicines European public assessment report (EPAR): Halaven, eribulin, Breast Neoplasms;Liposarcoma, Date of authorisation: 17/03/2011, Revision: 29, Status: Authorised
Source: